Related Experiment Video
Updated: May 26, 2026
11:32
Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Pneumonia and bacteremia due to Kytococcus schroeteri
Ola Blennow1, Katarina Westling, Inga Fröding
1Department of Medicine, Division of Infectious Diseases, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden. ola.blennow@karolinska.se
Journal of Clinical Microbiology
|December 14, 2011
Summary
Kytococcus schroeteri can cause severe infections in immunocompromised individuals. This case highlights successful treatment of Kytococcus schroeteri pneumonia and bacteremia using linezolid and trimethoprim-sulfamethoxazole.
Area of Science:
- Medical Microbiology
- Infectious Diseases
- Clinical Case Reports
Background:
- Kytococcus schroeteri is a commensal bacterium of human skin.
- This organism is an opportunistic pathogen, particularly in immunocompromised patients.
- Infections caused by Kytococcus schroeteri are rare but can be severe.
Observation:
- A case of pneumonia and bacteremia caused by Kytococcus schroeteri is presented.
- The patient was immunocompromised, increasing susceptibility to infection.
- The clinical presentation included severe respiratory and systemic illness.
Findings:
- Kytococcus schroeteri was identified as the causative agent of pneumonia and bacteremia.
- The patient received a combination therapy of linezolid and trimethoprim-sulfamethoxazole.
- Successful treatment and recovery were achieved with the prescribed antimicrobial regimen.
Implications:
- This case expands the understanding of Kytococcus schroeteri's pathogenic potential.
- It demonstrates the efficacy of linezolid and trimethoprim-sulfamethoxazole for treating serious Kytococcus schroeteri infections.
- Highlights the importance of considering Kytococcus schroeteri in the differential diagnosis of infections in immunocompromised hosts.
Related Concept Videos
01:29Pneumonia I: Introduction
Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
01:30Pneumonia I: Introduction
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:14Atypical Pneumonia
Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
01:29Pneumonia II: Pathophysiology
The pathophysiology of pneumonia involves the following steps:
01:30Pneumonia III: Complications and Assessment
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
01:28Pneumonia IV: Management
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: